Featured

Mayo Clinic doctors discuss the role clinical trials — research studies that test new treatments and other interventions — play in cancer care.

The presence of a specific genetic mutation — KRAS circulating tumor DNA (ctDNA) — strongly indicates a higher risk of spread and worse survival rates for people with pancreatic cancer.

The team identified specific proteins — fibronectin and smooth muscle actin — associated with resistance to immunotherapy treatment in colorectal cancer tissues.

Drs. Vincent Rajkumar and Rafael Fonseca explain what smoldering multiple myeloma is and how treating it could potentially delay or prevent multiple myeloma.

Dr. Travis Grotz, a Mayo Clinic surgical oncologist, shares what people should know about the signs and symptoms of stomach cancer.

Dr. Keith Knutson explains how the development of personalized lung cancer vaccines is giving patients hope.

Dr. Elizabeth Cathcart-Rake discusses a specialized clinic at Mayo Clinic in Rochester, Minnesota, designed to support LGBTQ+ people with breast cancer.

Daratumumab, a monoclonal antibody drug, significantly reduces the risk of progression to active multiple myeloma and improves overall survival compared to active monitoring.

Study demonstrates potentially effective treatment for people with bladder cancer who no longer respond to Bacillus Calmette-Guérin (BCG).

Dr. Elizabeth Cathcart-Rake, a medical oncologist specializing in breast cancer, clears up confusion about who should be screened for breast cancer and when.